One Way Holdings LLC Sells 14,489 Shares of Edwards Lifesciences Corporation $EW

One Way Holdings LLC reduced its position in Edwards Lifesciences Corporation (NYSE:EW) by 5.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 251,883 shares of the medical research company’s stock after selling 14,489 shares during the quarter. One Way Holdings LLC’s holdings in Edwards Lifesciences were worth $21,743,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Pin Oak Investment Advisors Inc. bought a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at about $26,000. TrinityBridge Ltd bought a new position in shares of Edwards Lifesciences during the second quarter valued at approximately $27,000. GK Wealth Management LLC purchased a new position in Edwards Lifesciences during the third quarter valued at approximately $26,000. RMG Wealth Management LLC purchased a new position in Edwards Lifesciences during the first quarter valued at approximately $26,000. Finally, Compass Financial Management LLC bought a new position in Edwards Lifesciences in the second quarter worth approximately $32,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Raymond James Financial increased their target price on Edwards Lifesciences from $100.00 to $103.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Wall Street Zen lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday. Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $87.00 to $101.00 in a research note on Friday, July 24th. Robert W. Baird decreased their price objective on Edwards Lifesciences from $94.00 to $90.00 and set a “neutral” rating for the company in a research note on Thursday, October 15th. Finally, JPMorgan Chase & Co. raised their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Friday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $101.16.

Insider Activity at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 544 shares of the company’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the transaction, the senior vice president directly owned 14,868 shares of the company’s stock, valued at $1,353,880.08. This represents a 3.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the transaction, the vice president owned 40,034 shares of the company’s stock, valued at $3,684,329.02. This trade represents a 1.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 5,045 shares of company stock valued at $451,596 in the last three months. 0.31% of the stock is owned by insiders.

Edwards Lifesciences Trading Down 0.1%

Edwards Lifesciences stock opened at $91.91 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The stock has a market cap of $52.92 billion, a PE ratio of 52.82, a price-to-earnings-growth ratio of 2.41 and a beta of 0.87. The stock has a 50-day moving average of $88.15 and a two-hundred day moving average of $85.43. Edwards Lifesciences Corporation has a one year low of $74.66 and a one year high of $96.29.

About Edwards Lifesciences

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.